P3781
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaA Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and LymphomaTreatment of Natural Killer/T Cell Lymphoma-Ⅲ/ⅣTreatment of Natural Killer/T Cell Lymphoma-I/IINHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic LymphomaGAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell LymphomaErwinase Study in Patients With Acute Lymphoblastic LeukemiaBortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaAugmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic LymphomaPegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCombination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic LeukemiaCombination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic LeukemiaTreatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTSPhase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal CancerRuxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic LeukemiaPrecision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALLTreatment of Hyperbilirubinemia Due to PEG-asparaginase and Inotuzumab Ozogamicin in Acute Lymphoblastic Leukemia (ALL)Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic LeukemiaA Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute LymphoblPalbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic LymphomaLow-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaTemsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaCombination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsAzacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene RearrangementCombination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic LeukemiaA Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic LeukaemiaClofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALLBiomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALLTrial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic LeukaemiaInternational Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaStandard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaBortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaModified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic LeukemiaCalaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic LeukemiaInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLySC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic LymphomaEverolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
P4844
Q61864749-21A9024D-9FCD-484E-A25F-0FD2D6C2A505Q61934649-AAA1E363-1659-491E-A748-02C74DA24F13Q61957610-5051915C-07AE-4847-BA4D-F8FE9DF77174Q61957611-F42975E8-2F47-4B9A-9C0F-8BF3665CB5CBQ61967240-D8E21968-B263-4DA6-9177-8E96039CE852Q61970041-F0D9AE5D-D60B-4659-8637-9D0A486C9831Q61979883-4D8FF8BD-2136-4B0F-BD4D-C8CAD88EFC72Q61980425-3CFE1BCE-A45D-400D-8CEF-A0EDD92E78B4Q61980960-45C32CF8-8C8E-402A-A889-2D6E6B225CF2Q61981000-C165AF35-EBE8-4428-BFD9-43E21FAB1EB4Q62026003-7F2A285D-2B4E-45C1-A133-84F1BE76F78DQ62106060-B639E3B0-3281-4DC6-9CD5-E4FED2A82D07Q62110587-CE8D1D20-2CD4-4B3B-BDF8-D28922F332E4Q62110671-105B3F38-1E89-47DF-A76F-4535E9A21A77Q63319090-B1D1D89D-3D2C-45CC-B864-6A5C8A72240CQ63338894-5323EEAE-EF50-476D-AD6B-D0F16739538FQ63397345-1B20C09A-B507-4366-969B-2A259B30651FQ63398830-D6424F49-D936-4995-8F1B-A92A4C16C4B4Q63398840-12C57792-BFF9-4110-89AA-759E19704262Q63535088-466A03F3-2E0D-438D-8558-0BA276A8EBC5Q63572193-14D4E74F-ACD6-4E8F-8610-21FE90005850Q63575221-04E87C1C-5803-4B71-9E7E-C12E0D1B28F5Q63577235-989514DE-A676-4991-9099-DC30C8425BB1Q63578656-A2E7B334-1B22-4825-A442-F6759FD1AB5EQ63807073-BA68DB8C-E64F-42FA-B71B-F2FA5280F922Q63807824-FF2FCB10-DB11-4DB8-96D6-865E396BD40AQ63807838-64FBC964-9385-4D49-A930-1443E56A9A73Q63807976-53BF5D4E-540E-48FB-89EC-51448A34C357Q63815648-5A2579D3-7373-40DE-A831-178E779DA27BQ63816596-727049D5-4647-4985-9922-5124B1DEADB5Q63816982-76F8E4F3-7F5E-4637-9B5D-A33CD0E6C28EQ63818817-105B9645-99F5-4A83-9B87-ECF16D012858Q63831190-090A7EC1-8462-420A-A164-384FBE50FF79Q63837611-2C291FFB-EE7E-4762-93DF-771E05866A90Q63844565-33CFD272-AAA2-4199-8A25-4A16796378C3Q64047583-276DB598-8CF6-4713-A0D5-55FCBC61FF6AQ64047714-F696983D-FDD5-4CAD-A412-6D694DEA62ADQ64151264-2FF82AC1-840D-4A0D-ABB4-826C3B8E42FBQ64187541-73699A43-00E2-48EE-A177-FB8333E0AE81Q64187550-E9AFBE7B-C487-4E32-9975-874866836115
P4844
description
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
composé chimique
@fr
name
Pegaspargasa
@es
Pegaspargase
@en
Pegaspargase
@vi
Pegaspargaza
@sh
Pegaspargaza
@sr
Pegaspargază
@ro
pegaspargase
@nn
بيغاسبارغاس
@ar
ペグアスパラガーゼ
@ja
type
label
Pegaspargasa
@es
Pegaspargase
@en
Pegaspargase
@vi
Pegaspargaza
@sh
Pegaspargaza
@sr
Pegaspargază
@ro
pegaspargase
@nn
بيغاسبارغاس
@ar
ペグアスパラガーゼ
@ja
altLabel
L-asparagine amidohydrolase
@en
Putative L-asparaginase precursor
@en
prefLabel
Pegaspargasa
@es
Pegaspargase
@en
Pegaspargase
@vi
Pegaspargaza
@sh
Pegaspargaza
@sr
Pegaspargază
@ro
pegaspargase
@nn
بيغاسبارغاس
@ar
ペグアスパラガーゼ
@ja
P2175
P31
P486
P592
P6366
P2115
N0000148371
P2167
P2275
Pegaspargase
@en
P231
130167-69-0
P267
P279
P2868
P3345
P3780
P486
P592
CHEMBL2108546
P6366
2780718877
P652
7D96IR0PPM